Progressively Reducing Regulatory Burden
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 4
Abstract
Principles of dissolution science have been applied to allow waiver of in vivo bioequivalence studies for oral immediate release solid dosage forms, providing certain stipulations are met. This approach reduces regulatory burden without sacrificing product quality and performance requirements that assure continuing equivalence. These principles are broadly applicable to other dosage forms and routes of administration. In this article, we postulate a further opportunity, which relies on a determination of “optimal performance” for nonsolution orally administered drug products. The determination can be applied to certain highly soluble and rapidly dissolving drug products without further study, paving the way possibly for even further reductions in regulatory burden.
Authors and Affiliations
Vinod P. Shah, Todd L. Cecil, Srini V. Srinivasan, Roger L. Williams
Keywords
Related Articles
- EP ID EP681696
- DOI 10.1208/s12248-014-9601-z
- Views 73
- Downloads 0
Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity
The online version of this article (doi:10.1208/s12248-013-9490-6) contains supplementary material, which is available to authorized users.
Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report
Modified release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety. Inappropriate control of drug release from such products may result in reduced ef...
Bioequivalence studies for levothyroxine
The Food and Drug Administration (FDA) Guidance for Bioavailability and Bioequivalence Studies for Levothyroxine has been challenged by companies that manufacture brand-name products. Their contention is that the current...
Influence of solvents on the variety of crystalline forms of erythromycin
The influence of the organic solvents widely used in the pharmaceutical industry (acetone, methylethylketone, ethanol, and isopropanol) both in the presence and in the absence of water on the crystallization behavior of...
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?